BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• BioCryst Pharmaceuticals has received a consensus rating of "Moderate Buy" from ten analysts, with nine recommending a buy and one a hold, reflecting positive outlook for the stock.
• The average price target among analysts for BioCryst Pharmaceuticals is $16.70, with some analysts setting targets as high as $18.00.
• Insider trading activity reported a director selling 70,000 shares at an average price of $8.51, reducing their ownership by 51.72%.

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $16.70.

Several equities analysts have recently commented on the stock. Wedbush upped their price objective on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a research note on Monday, June 30th. Needham & Company LLC reaffirmed a "buy" rating and set a $17.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, August 4th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 26th. Finally, Bank of America upped their price objective on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Tuesday, July 1st.

Insider Activity

In related news, Director Theresa Heggie sold 70,000 shares of the business's stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the transaction, the director owned 65,352 shares in the company, valued at $556,145.52. The trade was a 51.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Headlands Technologies LLC purchased a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at about $32,000. GAMMA Investing LLC increased its position in shares of BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after buying an additional 5,449 shares during the period. New Age Alpha Advisors LLC purchased a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at about $62,000. Family Legacy Financial Solutions LLC purchased a new position in shares of BioCryst Pharmaceuticals during the second quarter valued at about $72,000. Finally, Allspring Global Investments Holdings LLC purchased a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at about $79,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Stock Down 1.0%

BioCryst Pharmaceuticals stock opened at $7.55 on Tuesday. The company has a market capitalization of $1.58 billion, a PE ratio of -41.94, a P/E/G ratio of 1.53 and a beta of 1.13. The firm has a fifty day simple moving average of $8.21 and a two-hundred day simple moving average of $8.72. BioCryst Pharmaceuticals has a twelve month low of $6.01 and a twelve month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million for the quarter, compared to the consensus estimate of $149.59 million. The business's revenue was up 49.5% on a year-over-year basis. During the same period last year, the company posted ($0.06) earnings per share. As a group, equities analysts expect that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.